Kiniksa Pharmaceuticals International (KNSA) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 105.6% versus a gain of 29.4%. Over five years, KNSA leads with a +587.8% price change compared with +31.3% for TAK. Takeda Pharmaceutical is the larger company by market cap ($59.82 billion vs $6.22 billion), about 9.6 times the size.
On valuation, Takeda Pharmaceutical trades at a lower forward P/E (35.3x vs 49.3x for Kiniksa Pharmaceuticals International). Takeda Pharmaceutical pays a dividend yielding 1068.09%, while Kiniksa Pharmaceuticals International does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | TAK |
|---|---|---|
| Share price | $79.78 | $18.73 |
| Market cap | $6.22B | $59.82B |
| 1-day change | +1.31% | +1.11% |
| YTD return | +90.91% | +18.79% |
| 1-year return | +105.56% | +29.42% |
| 5-year return | +587.77% | +31.35% |
| P/E ratio (TTM) | 80.59 | — |
| Forward P/E | 49.32 | 35.33 |
| EPS (TTM) | $0.99 | $-0.34 |
| Dividend yield | 0.00% | 1068.09% |
| Annual dividend | $0.00 | $200.00 |
| Revenue (latest FY) | $677.56M | — |
| Revenue growth (YoY) | +60.09% | — |
| Net income (latest FY) | $59.01M | — |
| Gross margin | 88.54% | — |
| Operating margin | 11.40% | — |
| Net margin | 8.71% | — |
| 52-week high | $82.94 | $19.10 |
| 52-week low | $35.20 | $12.99 |
| Distance from 52-week high | -3.81% | -1.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +22.84% | +17.28% |
| Average volume | 573.74K | 3.04M |
| Shares outstanding | 48.29M | 3.19B |
| Employees | 366 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 9.6 times larger than Kiniksa Pharmaceuticals International by market value ($59.82B vs $6.22B).
- KNSA has outperformed TAK by 76.1 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1068.09% vs 0.00%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
KNSA vs TAK FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.82B compared with $6.22B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, KNSA or TAK?
KNSA returned +105.56% over the past 12 months, compared with +29.42% for TAK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kiniksa Pharmaceuticals International or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 1068.09%, while Kiniksa Pharmaceuticals International does not currently pay a regular dividend.
Are Kiniksa Pharmaceuticals International and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.